SEC Filing – Corcept Therapeutics, Incorporated

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Maduck Sean

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/07/2018

3. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,024	D
Common Stock	10,000	I	See Footnote⁽¹⁾
Common Stock	10,000	I	See Footnote⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽³⁾	11/01/2022	Common Stock	45,000	2.24	D
Stock Option (Right to Buy)	⁽³⁾	01/30/2023	Common Stock	20,000	2.08	D
Stock Option (Right to Buy)	⁽³⁾	11/19/2023	Common Stock	25,000	1.92	D
Stock Option (Right to Buy)	⁽³⁾	02/06/2024	Common Stock	40,000	3.02	D
Stock Option (Right to Buy)	⁽⁴⁾	08/07/2024	Common Stock	100,000	2.61	D
Stock Option (Right to Buy)	⁽⁵⁾	02/18/2025	Common Stock	250,000	3.29	D
Stock Option (Right to Buy)	⁽⁶⁾	02/26/2026	Common Stock	150,000	3.88	D
Stock Option (Right to Buy)	⁽⁷⁾	05/02/2026	Common Stock	150,000	5.05	D
Stock Option (Right to Buy)	⁽⁸⁾	02/10/2027	Common Stock	400,000	8.27	D

Explanation of Responses:

1. Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

2. Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.

3. Fully exercisable.

4. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of August 1, 2014, so that the total number of shares subject to this option becomes fully vested and exercisable on August 1, 2018.

5. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 18, 2015, so that the total number of shares subject to this option becomes fully vested and exercisable on February 18, 2019.

6. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 26, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on February 26, 2020.

7. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of April 27, 2016, so that the total number of shares subject to this option becomes fully vested and exercisable on April 27, 2020.

8. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021.

Remarks:

Senior Vice President, Commercial

	/s/ Sean Maduck	02/09/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.